US Patent Issued to INNOBATION BIO on July 29 for "Humanized antibody specific for CD22 and chimeric antigen receptor using the same" (South Korean Inventors)

ALEXANDRIA, Va., July 30 -- United States Patent no. 12,371,492, issued on July 29, was assigned to INNOBATION BIO Co. LTD. (Seoul, South Korea).

"Humanized antibody specific for CD22 and chimeric antigen receptor using the same" was invented by Seung Koo Kim (Yongin-si, South Korea) and Ki Tae Kim (Seoul, South Korea).

According to the abstract* released by the U.S. Patent & Trademark Office: "A humanized antibody specific for CD22 and a chimeric antigen receptor using the same, and, in some aspects, a chimeric antigen receptor including the antibody or a CD19xCD22 antibody, a CAR-T cell expressing the chimeric antigen receptor, and a pharmaceutical composition including the same for preventing or treating a disease mediated by B cells."...